Announcement on the resolutions of the 10th meeting of the 8th board of directors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
Stock Code: Joincare Pharmaceutical Group Industry Co.Ltd(600380) Stock Name: Joincare Pharmaceutical Group Industry Co.Ltd(600380) Announcement No.: pro 2022047 Joincare Pharmaceutical Group Industry Co.Ltd(600380)
Announcement of resolutions of the 10th meeting of the 8th board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Joincare Pharmaceutical Group Industry Co.Ltd(600380) (hereinafter referred to as the company) the 10th meeting of the 8th board of directors was sent out in the form of email and telephone confirmation on Friday, April 15, 2022, and held in the form of on-site and video conference in room 2, Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group building, No. 17, Langshan Road, North District, high tech Zone, Nanshan District, Shenzhen at 14:00 p.m. on Friday, April 22, 2022. Nine directors should attend the meeting, nine actually attended the meeting, and three members of the board of supervisors, the president and other senior managers of the company attended the meeting as nonvoting delegates, which was in line with the provisions of the company law and the articles of association. The meeting considered and passed the following proposals:
1、 Deliberated and adopted the report of the first quarter of Joincare Pharmaceutical Group Industry Co.Ltd(600380) 2022
For details, please refer to China Securities Journal, Shanghai Securities News, securities times, securities daily and Shanghai Stock Exchange (www.sse. Com. CN.) on April 25, 2022 The first quarter report of Joincare Pharmaceutical Group Industry Co.Ltd(600380) 2022 announced.
Voting: 9 in favor, 0 abstention and 0 opposition.
2、 Deliberated and passed the proposal on the company’s phase II shareholding plan (Draft) of the shareholding plan of medium and long-term business partners and its summary
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the guiding opinions on the pilot implementation of employee stock ownership plan by listed companies, the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 1 – standardized operation and other relevant laws, administrative regulations, normative documents and the articles of association Relevant provisions of Joincare Pharmaceutical Group Industry Co.Ltd(600380) medium and long term business partner shareholding plan (Revised Draft) have formulated the company’s phase II shareholding plan of medium and long term business partner shareholding plan (Draft) and its summary.
The scope of holders of the plan includes senior managers in the company, core personnel such as R & D, production, sales and management who have made outstanding contributions to the performance of the assessment period or have a significant impact on the future performance of the company. The total number of the current shareholding plan is no more than 50. The final participants are determined according to the actual subscription. The source of funds is the special fund for the shareholding plan withdrawn by the company, with a total amount of 75.76 million yuan.
Announcement on the resolutions of the 10th meeting of the 8th board of directors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
For details of the above contents, the company published on China Securities Journal, securities times, Shanghai Securities News, securities daily and the website of Shanghai Stock Exchange (www.sse. Com. CN) on April 25, 2022 The disclosed summary of the second phase of the shareholding plan (Draft) of the shareholding plan of Joincare Pharmaceutical Group Industry Co.Ltd(600380) medium and long term business partners and the website of Shanghai Stock Exchange (www.sse. Com. CN.) The second phase of the shareholding plan of Joincare Pharmaceutical Group Industry Co.Ltd(600380) medium and long term business partners (Draft) disclosed.
Voting results: 6 in favor, 0 against and 0 abstention. Directors Yu Xiong, Qiu Qingfeng and Lin Nanqi were affiliated directors and avoided voting.
This proposal must be submitted to the general meeting of shareholders of the company for deliberation.
3、 Deliberated and passed the proposal on requesting the general meeting of shareholders to authorize the board of directors to handle matters related to the second phase of the shareholding plan of the company’s medium and long-term business partners
In order to ensure the smooth implementation of the second phase of the shareholding plan of the company’s medium and long-term business partners, the board of directors requests the general meeting of shareholders to authorize the board of directors to decide or deal with matters related to the second phase of the shareholding plan of the medium and long-term business partners, including but not limited to:
1. Authorize the board of directors to withdraw the annual special incentive fund and determine the specific distribution plan;
2. Authorize the board of directors to decide on the changes of the plan, including but not limited to the disqualification of the holder, the change of the holder’s share, handling the inheritance of the deceased holder, early termination of the shareholding plan and other matters in accordance with the provisions of the plan; 3. Authorize the board of directors to make a decision on the extension or shortening of the duration of the plan;
4. Authorize the board of directors to make decisions on the determination and change of asset managers, custodians and other intermediaries under the plan;
5. Authorize the board of directors to explain the relevant contents not listed in the plan;
6. Authorize the board of directors to handle all other matters required by the plan, except for the rights that need to be reviewed and exercised by the general meeting of shareholders as clearly stipulated in relevant documents.
Voting results: 6 in favor, 0 against and 0 abstention. Directors Yu Xiong, Qiu Qingfeng and Lin Nanqi were affiliated directors and avoided voting.
This proposal must be submitted to the general meeting of shareholders of the company for deliberation.
4、 Deliberated and passed the proposal on convening the 2021 annual general meeting of shareholders of the company
The company plans to hold the 2021 annual general meeting of shareholders of the company on May 18, 2022 by combining on-site meeting and online voting. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on April 25, 2022 Materials of Joincare Pharmaceutical Group Industry Co.Ltd(600380) 2021 annual general meeting of shareholders, China Securities Journal, Shanghai Securities News, securities times, securities daily and Shanghai Stock Exchange
Announcement on the resolutions of the 10th meeting of the 8th board of directors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
Website of Stock Exchange (www.sse. Com. CN.) Notice of Joincare Pharmaceutical Group Industry Co.Ltd(600380) on convening the 2021 annual general meeting of shareholders (p.2022048).
Voting result: 9 affirmative votes; Negative vote: 0; There were no abstentions.
It is hereby announced.
Joincare Pharmaceutical Group Industry Co.Ltd(600380) April 25, 2002
